, there is little evidence that either renal function or hearing loss shows meaningful improvement with time.
Three patients have relapsed; one with a pineal germinoma who relapsed in the abdomen six months after diagnosis, and two with sacrococcygeal teratomas and lung metastases. Two of these remain in second complete remission after further treatment. There was one death from probable bleomycin pulmonary toxicity. We conclude that this regimen is simple to administer and, apart from myelosuppression, it is well tolerated. It appears to have comparable efficacy to cisplatin-based regimens but with much less nephrotoxicity and ototoxicity and avoids the use of alkylating agents and anthracyclines.
Dramatic improvement in cure rates of adults with malignant germ cell tumours using cisplatin-based regimens have been mirrored in paediatric practice (Einhorn & Donohue, 1977; Peckham et al., 1983; Williams et al., 1987; Pinkerton et al., 1986; Mann et al., 1987) . With short-duration chemotherapy, non-mutilating surgery and avoidance of radiotherapy or alkylating agents, the majority of children, including many with metastatic MGCT, can be cured. With such a favourable outcome emphasis is now placed on avoiding immediate and delayed toxicity. The PVB (cisplatin, vinblastine, bleomycin) or BEP (bleomycin, etoposide, cisplatin) regimens, without alkylating agents, probably avoid sterility and reduce second malignancy risks but are accompanied by significant renal and auditory toxicity. Even with careful hydration, mannitol and monitoring of glomerular filtration rate (GFR) by 51Cr-EDTA clearance, the majority of children will have a significant fall in GFR. Though hearing loss affects only high frequencies in most cases, it is still of clinical significance (Brock et al., 1988) . Although long-term studies are few (Brock et al., 1988; Koliouskas et al., 1985) , there is little evidence that either renal function or hearing loss shows meaningful improvement with time.
Substitution for cisplatin by a less toxic analogue such as carboplatin has been shown to be effective in ovarian cancer (Calvert et al., 1982; Wiltshaw et al., 1985) and this drug has clear activity in adult Phase II studies with MGCT (Horwich et al., 1988) . There is, however, little or no evidence that significant non-cross resistance exists in cisplatin-resistant tumours and its use in the JEB regimen is primarily to avoid toxicity. In this regimen, carboplatin is given at a dose based on renal function calculated from the Calvert formula (Calvert et al., 1989) . This is predicted to produce an area under the drug concentration curve (AUC) which may lead to significant but manageable myelosuppression but possibly maximum therapeutic effect. Early studies in adults show clearly that inferior results are achieved with carboplatin unless the dose is pushed to myelosuppressive levels .
Etoposide and bleomycin are used as in the standard BEP regimen (Peckham et al., 1983) . There is some controversy about the necessity of weekly rather than 3-weekly bleomycin. In this study, if it was possible to monitor lung function, children were given this drug weekly. Infants, whose lung function could not be tested, received bleomycin 3-weekly after the first two cycles of chemotherapy.
Patients and methods
Twenty-one children aged 1 to 16 years (median 11 years) received the JEB regimen. Nineteen were previously untreated and two had received single courses of PVB and BEP chemotherapy respectively. Clinical details are shown in Table I . Serum markers (a-fetoprotein and P-HCG) were estimated in all patients by immunoassay. Staging investigations included PA and lateral chest X-ray, CT chest scan, isotope bone scan and abdominal ultrasound or CT scan. Lymphography was not performed.
Indications for chemotherapy were the presence of metastatic disease in lung (6), lymph nodes (6), or peritoneum (1); bulky, unresectable primary tumour (5), peritoneal spill at surgery (3), or an intracranial primary (2). The testis was the primary site in 6 patients, ovary in 8 and sacrococcygeal area in 4. A one-year-old infant with a large vaginal tumour was treated electively with chemotherapy alone to avoid mutilating surgery. One boy with a pineal germinoma received JEB after complete resection and before irradiation. A second patient with a pineal tumour had undergone surgery but developed rapidly progressive disease within a month of this. a-FP was elevated in 19 patients, P-HCG in 8. In no patient was both x-FP and P-HCG normal. The chemotherapy is outlined in Figure 1 . Bleomycin (15 mg m-2) was given weekly as a slow intravenous infusion. Etoposide (120 mg m2) was administered daily x 3 as a 1 to 3 hour infusion and carboplatin infused over one hour. The formula for calculating the dose of carboplatin was based on the uncorrected "Cr-EDTA clearance. In four children the GFR was not measured before treatment and doses based on surface area were given (400-500 mg m2). In four the carboplatin dose was given according to surface area despite the Correspondence: C.R. Pinkerton. Received 29 January 1990; and in revised form 22 March 1990.
GFR being known, and in three patients an AUC of less than 5 mg ml-' min'l was electively chosen by the physician.
Tumour response was reassessed after 2 and 4 courses and CR documented using markers and imaging with X-ray or CT scan. Patients were given a minimum of four courses of JEB with additional cycles dependent on initial bulk of disease and the time to CR. Usually, chemotherapy was continued for 2 courses beyond CR. Monitoring Toxicity Estimates of plasma urea and creatinine have been shown to be inaccurate indicators of renal impairment in children receiving cisplatin (Womer et al., 1985) . 5'Cr-EDTA GFR was therefore estimated before treatment and repeated during treatment in most patients. Formal audiometry was done during and following treatment in patients old enough to co-operate. The hearing was graded according to a scale devised specifically to quantify cisplatin-related ototoxicity in children (Brock et al., 1988) . In patients who could cooperate, spirometric respiratory function tests and CO diffusion tests were performed at intervals during and following treatment.
Results

Tumour response and outcome
The total number of courses given ranged from 4 to 6 (median 4). Marker CR was achieved in all patients after between two and four courses of chemotherapy. The estimated serum a-FP tt ranged from 3 to 12 days (median 7 days) and of P-HCG from 3 to 15 days (median 4) (Table III) . One boy with a pineal germinoma (case No 3), who had no measurable disease following initial surgery, developed progressive abdominal disease with multiple peritoneal seedlings, probably related to a ventriculoperitoneal shunt. Despite cranio-spinal irradiation and introduction of an intensive cisplatin-containing regimen he failed to respond. Patient 5 with a sacrococcygeal primary and lung metastases, achieved rapid CR but tumour recurred at the primary site 4 months after completion of treatment. Coccyxectomy had not initially been performed electively because of radiological CR at primary and metastatic sites. Patient 16 developed recurrent lung metastases 6 months after having achieved CR.
With chemotherapy alone complete remission of disease on X-ray or CT scan occurred in 12 of 18 evaluable patients; residual primary disease was completely resected in 4 cases; 2 showed active tumour and 2 mature teratoma (Table IV) . 'Second look' surgery was performed in 6 patients with no imageable disease and confirmed clinical CR in each.
Minor residual abnormalities were seen on CT scan in three patients but secondary surgery was not performed.
These abnormalities were in the abdomen in two cases and in the lung in a third child. All abnormal CT images subsequently resolved and the patients remain free from disease. One patient (number 10), developed progressive peritoneal disease on CT scan during chemotherapy despite normalization of a-FP levels. At laparotomy, the tumour was resected and shown to consist entirely of differentiated teratoma. No further treatment was given and she remains free from disease 15 months from diagnosis. Hearing was not evaluated in 7 patients because of their young age. In one of 12 patients, adequately evaluated, there was evidence of high tone hearing loss during treatment (20 dB loss at 4 KHz), but this returned to normal 3 months later. 5"Cr-EDTA clearance declined > 10% from the original value in 3 of 12 patients adequately studied; 12, 15 and 20% respectively. (See Table II) . 
Discussion
This pilot study demonstrates both the efficacy and the tolerability of substituting carboplatin for cisplatin, combined with etoposide and bleomycin, in paediatric MGCT. In this regimen, a carboplatin AUC of 5-6mgml1' min, which in children with normal renal function is equivalent to approximately 600 mg m2, was recommended. This is somewhat higher than the AUC recommended in adults (4-5) which is predicted to result in moderately severe thrombocytopenia (Calvert et al., 1989) . As a single agent, at a dose of 400 mg m-2, carboplatin has produced high response rates in untreated patients with localized seminomatous and nonseminomatous germ cell tumours (NSGCT) (Horwich et al., 1988) . In one study using JEB in poor risk NSGCT in adults only 40% achieved CR with chemotherapy and surgery (Motzer et al., 1987) . In that study, however, the dose of carboplatin was only 350 mg m-2 which would yield an AUC in the range of 2-3 mg ml min. With a higher dose of carboplatin and an estimated AUC of over 4 mg ml-' min-, 39 out of 39 previously untreated metastatic NSGCT patients achieved complete remission . Because of concern about compromising antitumour activity an AUC of 5-6 was recommended in this study. Comparatively severe myelosuppression was expected and accepted as a trade-off against reduced renal and auditory toxicity. Formal randomised studies comparing the regimen against PVB or BEP are in progress in adults.
This study confirms that carboplatin is not associated with the ototoxicity seen with the BEP regimen. There was a small decline in GFR in a minority of children but in adults this has been clearly shown to be transient (Hardy et al., 1990) .
The role of bleomycin has not been addressed in this study but major reservations have been expressed in the past about weekly administration of this drug. Deaths from respiratory failure have been reported in children receiving PVB (Mann et al., 1987) and although other contributory factors may have been involved, there is some reason for concern. A link between cisplatin nephrotoxicity and bleomycin toxicity has been suggested (Dalgleish et al., 1984) . It is of note that one patient in this series developed clear evidence of lung toxicity although renal function remained normal after carboplatin. A small non-randomised study in adults has suggested that a reduced dose of bleomycin adversely affects the efficacy of BEP, but this was only in patients where the etoposide dose was also suboptimal (Brada et al., 1987) . By contrast, with full dose etoposide and cisplatin, the results were impressive despite the reduction to 3-weekly bleomycin. Current studies of BEP against EP in small bulk disease show little difference (Levi et al., 1986; Stoter et al., 1987) but the question has not been settled in high-risk patients. Limiting weekly bleomycin to the first two cycles in patients who cannot have lung function tests done is an option, or alternatively, only monthly treatment could be given in all patients. At present, there is a reluctance to omit the drug altogether in children, but once the results of randomised studies in adults are available this may be indicated. With the JEB regimen the response rate is comparable to that in children receiving cisplatin based regimens, with or without the addition of alkylating agents (Pinkerton et al., 1986 , Flamant et al., 1984 . With extra-cranial primaries a CR rate of 65% with chemotherapy alone, and 84% with chemotherapy plus surgery was achieved. All three patients not achieving CR have had minimal CT abnormalities which have remained unchanged, or resolved.
The role of surgery in gonadal disease is comparatively clear and is a useful way to confirm CR after chemotherapy or to resect any residual active disease. In the case of sacrococcygeal disease the necessity of coccyxectomy after radiological CR has been questioned. This procedure is however justified as an elective measure because of the difficulty in being sure that there is no residual tumour in this complex bony structure. The operation should be safe and without sequelae. In one child in the present series (No 5) disease recurred locally in the coccyx despite apparent CR.
Radiotherapy has little role in paediatric MGCT except in the event of refractory or relapsed disease. It continues to be used in pineal tumours because of reservations about the reliability of drug access to the CNS. It is becoming clear that this concern may be unfounded in some cases (Rustin et al., 1989) . There are, however, no reports yet of large series where radiotherapy was not given electively. It is likely that information will be gained from small infants in whom irradiation is omitted owing to concern about late sequelae.
Although there were no patients with very bulky mediastinal primaries or bone marrow or bone metastases, this was a comparatively high risk group and included six children with lung metastases and six with nodal disease. The risk categories devised for adult MGCT cannot readily be applied to paediatric patients. The absolute peak serum x-FP or P-HCG are not of the same significance as in adults provided levels decline within a relatively short half-life. 'Bulk disease' is difficult to define in the small child because the absolute tumour volume may be of more importance than volume in relation to the child's size. In adults, extragonadal tumours, mediastinal tumours in particular, continue to pose a therapeutic problem (Logothetis et al., 1985) . This may be a consequence of bulk disease or difficulty achieving complete resection of residual disease. It is of note that prognosis appears better with pure yolk sac histology in this subgroup. It is likely that JEB will not be sufficient for some patients and alternative strategies such as high-dose platinum and etoposide or high-dose intensity regimens such as the BEP/ BOP or POMB/ACE may be necessary Newlands et al., 1983) . Evaluation of the JEB regimen in unselected MGCT patients on a multicentre basis is currently underway by the United Kingdom Children Cancer Study Group. This study may help to define if there is a high risk group of patients in whom more toxic chemotherapy is justifiable.
